Features October 2010 Issue

Report of ARBs and Increased Cancer Risk is Overstated

Study data arenít sufficient for a hard-and-fast conclusion; if you are taking an ARB for hypertension, thereís no cause for alarm.

Researchers who examined data from studies on angiotensin-receptor blockers (ARBs) reported that patients taking an ARB had a higher incidence of new cancer occurrence (7.2 percent) than patients who were not taking an ARB (6.0 percent). The findings, which were published in the July 2010 issue of The Lancet Oncology, got a lot of media coverage, some of which overstated the link between ARBs and cancer risk, sparking unwarranted concern by patients taking ARBs.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.